about
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesisResidual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutationSWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2Integrated genetic and pharmacologic interrogation of rare cancersAn integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer.Systematic genomic and translational efficiency studies of uveal melanoma.Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progressionParallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesisIdentification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers.MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.A PGC1α-mediated transcriptional axis suppresses melanoma metastasis.In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.ARID1B is a specific vulnerability in ARID1A-mutant cancers.Defining a Cancer Dependency Map.PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer.The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization.PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.PGC1α promotes tumor growth by inducing gene expression programs supporting lipogenesis.Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.Characterizing genomic alterations in cancer by complementary functional associations.Complementary information derived from CRISPR Cas9 mediated gene deletion and suppressionPIK3CA mutant tumors depend on oxoglutarate dehydrogenase.A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines.CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor.Functional Genomic Characterization of Cancer Genomes.TRTH-15. RESISTANCE MECHANISMS TO BET-BROMODOMAIN INHIBITION IN MYC-AMPLIFIED MEDULLOBLASTOMA.Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.BIOL-04. INTEGRATED COPY-NUMBER AND CANCER DEPENDENCY ANALYSIS REVEALS ALTERED SPLICEOSOME STOICHIOMETRY AS A NOVEL VULNERABILITY IN GENOMICALLY DISRUPTED CANCERS.Genetic and transcriptional evolution alters cancer cell line drug responseAbstract LB-126: ARID1B is a specific vulnerability in ARID1A-mutant cancersImproved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integrationIdentification of ADAR1 adenosine deaminase dependency in a subset of cancer cellsSelective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitryGenome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma
P50
Q24306274-C7C0AFBE-BCE9-4206-9FF1-DABB093E3114Q24320038-68E0C9EB-D4D6-4D2F-8B0B-FE03AC6A9D61Q28269618-85DC052C-3850-47CC-A803-5C1900106BCEQ28829289-64365B1C-EE86-4FEE-8CD1-438818DAB916Q33728558-4F687E5E-CB4A-4E47-B938-4F3652D7174FQ33778295-220F48BA-EBE8-40C9-A9AA-3B88E088DE0BQ33827309-A5A86A9F-74BD-42FB-AE1E-16D4F6497B7EQ35609041-42BF1652-9636-4A4C-8FE6-DB5CFAF049C9Q36449325-C2C613F5-5E0B-40A9-BFA5-891C2468CDE4Q36586426-8FA1ED03-4AD9-4937-8D60-222E57EDA23AQ37164922-EF389B81-C7B0-4B73-87C2-8A987225A82CQ37203229-509B1F0A-8808-49F0-895A-77CA46EE00DCQ37510470-5A14E892-663D-43A7-A63F-65D7B598E42BQ37519684-35BEC335-8E03-41C9-9085-619F6B93BE6FQ38276153-B976F6DD-5673-4A67-BB7E-95ACC89C7386Q38696195-4EC10848-58BD-4DBF-AEFB-399B36460657Q38698803-32A0FDD1-A827-4741-BBCA-8E6F22B5E391Q38739798-1C66C4F2-E4B0-45AA-BB10-8D9F446868E1Q38972458-05F0FBD4-A2CF-49BF-A96B-A5F8B398E913Q38996812-62CD8314-1CA3-4EAF-8F6D-62C783DC9FF0Q39193337-2B7747F2-BE9D-4810-8A3B-259B2AD3E748Q39474407-84227F16-6A2B-460F-A6CE-280369105283Q39711118-7E9685E9-8262-4EFE-9374-5B9BA62FBCD5Q42219637-8D14EDD8-0E94-43BD-A796-FEA87AC765CBQ42224452-EDEF1076-D0EB-4C65-89EC-EEA7A7B6883CQ42580090-6D07A33E-430A-49DF-B047-1F350F95A1E3Q42695612-A518A54B-B3E8-4A3F-BD91-32701A4EF5F3Q46167320-9F4F30DC-1BC4-4376-BD8E-6D14FB0CE6A4Q47627028-DD12B3F4-9804-4A30-B540-5B23B7EEF774Q47723106-8CFABF26-BE77-4629-AAD9-68BB04A38A6CQ48747209-BBF03B00-FA2C-4894-A85E-5DD29D51DC47Q55003588-1630C3BA-1E58-435D-ADCE-6FDE4AED5AA3Q55088548-559CE7D4-B5CD-48F8-92EA-316097722C15Q55139102-07B736D2-5949-4373-BFF7-9224BAC07FE4Q56550183-87DB54AB-EDC1-4F58-B4C3-C002800869FBQ58063421-37B31AC5-C84A-4466-8F20-D8B0BA1F258EQ58617552-575262CD-D440-4A88-A7AB-BF0C2AC13B52Q60300373-21E8BAC2-174D-4E51-9235-E6018DA9416DQ61570960-BBAA7619-3112-4D55-8B90-852D6469C8ADQ61570969-2E00FA42-DEF7-46B0-92B0-6B409E5E30C6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francisca Vazquez
@ast
Francisca Vazquez
@en
Francisca Vazquez
@es
Francisca Vazquez
@nl
type
label
Francisca Vazquez
@ast
Francisca Vazquez
@en
Francisca Vazquez
@es
Francisca Vazquez
@nl
prefLabel
Francisca Vazquez
@ast
Francisca Vazquez
@en
Francisca Vazquez
@es
Francisca Vazquez
@nl
P106
P21
P31
P496
0000-0002-2857-4685